Cart
sales@molnova.com
Olokizumab
CAS No. 1007223-17-7
Olokizumab( —— )
Catalog No. M36700 CAS No. 1007223-17-7
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), primarily used in rheumatoid arthritis (RA) research .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 566 | In Stock |
|
| 10MG | 845 | In Stock |
|
| 25MG | 1226 | In Stock |
|
| 50MG | 1646 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOlokizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOlokizumab (CDP 6038) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), primarily used in rheumatoid arthritis (RA) research .
-
DescriptionOlokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1007223-17-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3(6):e119.?
molnova catalog
related products
-
IPSU
IPSU is an antagonist of OX2 receptor. IPSU Exhibits approximately six-fold selectivity for OX2 versus OX1 receptors.
-
Alclofenac
Alclofenac has a significant effect on the acute phase protein response and the degree of L-tryptophan binding to plasma protein and can be used in the treatment of patients with chronic rheumatism.
-
Fluralaner
Fluralaner is an isoxazoline ectoparasiticide. It potently and selectively inhibits binding of the GABA receptor channel blocker EBOB to housefly head membranes (IC50: 455 pM).
